-
1
-
-
0032924934
-
Cytochrome P-450 3A4: Regulation and role in drug metabolism
-
Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism, Annu Rev Pharmacol Toxicol. 1999 ; 39: 1-17.
-
(1999)
Annu Rev Pharmacol Toxicol
, vol.39
, pp. 1-17
-
-
Guengerich, F.P.1
-
2
-
-
0033972441
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
-
Dresser GK, Spence JD, Bailey DG Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 ; 38: 41-57.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 41-57
-
-
Dresser, G.K.1
Spence, J.D.2
Bailey, D.G.3
-
3
-
-
0030009690
-
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo
-
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol. 1996 ; 16: 104-112.
-
(1996)
J Clin Psychopharmacol
, vol.16
, pp. 104-112
-
-
Von Moltke, L.L.1
Greenblatt, D.J.2
Duan, S.X.3
Harmatz, J.S.4
Wright, C.E.5
Shader, R.I.6
-
4
-
-
0141542650
-
Effect of mibefradil on CYP3A4 in vivo
-
Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, Greenberg HE Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003 ; 43: 1091-1100.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 1091-1100
-
-
Veronese, M.L.1
Gillen, L.P.2
Dorval, E.P.3
Hauck, W.W.4
Waldman, S.A.5
Greenberg, H.E.6
-
5
-
-
0033977595
-
Metabolic interactions between mibefradil and HMGCoA reductase inhibitors: Linking in vitro with in vivo information
-
Mück W. Metabolic interactions between mibefradil and HMGCoA reductase inhibitors: linking in vitro with in vivo information. Br J Clin Pharmacol. 2000 ; 49: 87-90.
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 87-90
-
-
Mück, W.1
-
6
-
-
0032700543
-
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
-
Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999 ; 66: 461-471.
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 461-471
-
-
Tsunoda, S.M.1
Velez, R.L.2
Von Moltke, L.L.3
Greenblatt, D.J.4
-
7
-
-
0029972195
-
The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism
-
Holtbecker N., Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos. 1996 ; 24: 1121-1123.
-
(1996)
Drug Metab Dispos
, vol.24
, pp. 1121-1123
-
-
Holtbecker, N.1
Fromm, M.F.2
Kroemer, H.K.3
Ohnhaus, E.E.4
Heidemann, H.5
-
8
-
-
0033309227
-
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
-
McCrea J., Prueksaritanont T., Gertz BJ, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999 ; 39: 1212-1220.
-
(1999)
J Clin Pharmacol
, vol.39
, pp. 1212-1220
-
-
McCrea, J.1
Prueksaritanont, T.2
Gertz, B.J.3
-
9
-
-
1642494659
-
Cocktail" approaches and strategies in drug development: Valuable tool or flawed science
-
Zhou H., Tong Z., McLeod JF " Cocktail" approaches and strategies in drug development: valuable tool or flawed science ? J Clin Pharmacol. 2004 ; 44: 120-134.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 120-134
-
-
Zhou, H.1
Tong, Z.2
McLeod, J.F.3
-
10
-
-
0031868142
-
Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations
-
Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther. 1999 ; 63: 617-622.
-
(1999)
Clin Pharmacol Ther
, vol.63
, pp. 617-622
-
-
Kovacs, S.J.1
Martin, D.E.2
Everitt, D.E.3
Patterson, S.D.4
Jorkasky, D.K.5
-
11
-
-
0037200017
-
Metabolism of 4β-hydroxycholesterol in humans
-
Bodin K., Andersson U., Rystedt E., et al. Metabolism of 4β-hydroxycholesterol in humans. J Biol Chem. 2002 ; 277: 31534-31540.
-
(2002)
J Biol Chem
, vol.277
, pp. 31534-31540
-
-
Bodin, K.1
Andersson, U.2
Rystedt, E.3
-
12
-
-
0035914368
-
Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: Evidence for involvement of cytochrome P450 3A4
-
Bodin K., Bretillon L., Aden Y., et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem. 2001 ; 276: 38685-38689.
-
(2001)
J Biol Chem
, vol.276
, pp. 38685-38689
-
-
Bodin, K.1
Bretillon, L.2
Aden, Y.3
-
13
-
-
64749098311
-
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS
-
Honda A., Yamashita K., Hara T., et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res. 2009 ; 50: 350-357.
-
(2009)
J Lipid Res
, vol.50
, pp. 350-357
-
-
Honda, A.1
Yamashita, K.2
Hara, T.3
-
14
-
-
42149130238
-
Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy
-
Wide K., Larsson H., Bertilsson L., Diczfalusy U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy. Br J Clin Pharmacol. 2008 ; 65: 708-715.
-
(2008)
Br J Clin Pharmacol
, vol.65
, pp. 708-715
-
-
Wide, K.1
Larsson, H.2
Bertilsson, L.3
Diczfalusy, U.4
-
15
-
-
54249101311
-
Cytochrome P450 induction by rifampicin in healthy subjects: Determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β-hydroxycholesterol
-
Kanebratt K., Diczfalusy U., BàCurrency signckström T. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β- hydroxycholesterol. Clin Pharmacol Ther. 2008 ; 84: 589-594.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 589-594
-
-
Kanebratt, K.1
Diczfalusy, U.2
BàCurrencysignckström, T.3
-
16
-
-
58149129621
-
4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity: Stability and half-life of elimination after induction with rifampicin
-
Diczfalusy U., Kanebratt KP, Bredberg E., Andersson TB, Böttiger Y., Bertilsson L. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity: stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009 ; 67: 38-43.
-
(2009)
Br J Clin Pharmacol
, vol.67
, pp. 38-43
-
-
Diczfalusy, U.1
Kanebratt, K.P.2
Bredberg, E.3
Andersson, T.B.4
Böttiger, Y.5
Bertilsson, L.6
-
17
-
-
67651183629
-
-
Tomalik-Scharte D., Lütjohann D., Doroshyenko O., Frank D., Jetter A., Fuhr U. Plasma 4β-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther. 2009 ; 86 (2). 147-153.
-
(2009)
Plasma 4β-hydroxycholesterol: An Endogenous CYP3A Metric? Clin Pharmacol Ther
, vol.86
, Issue.2
, pp. 147-153
-
-
Tomalik-Scharte, D.1
Lütjohann, D.2
Doroshyenko, O.3
Frank, D.4
Jetter, A.5
Fuhr, U.6
-
18
-
-
45849151673
-
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels
-
Josephson F., Bertilsson L., Böttiger Y., et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels. Eur J Clin Pharmacol. 2008 ; 64: 775-781.
-
(2008)
Eur J Clin Pharmacol
, vol.64
, pp. 775-781
-
-
Josephson, F.1
Bertilsson, L.2
Böttiger, Y.3
-
19
-
-
40049103597
-
4β-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
-
Diczfalusy U., Miura J., Roh HK,, et al. 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008 ; 18: 201-208.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 201-208
-
-
Diczfalusy, U.1
Miura, J.2
Roh, H.K.3
-
20
-
-
10744232330
-
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
-
Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER)
-
Bjornsson TD, Callaghan JT, Einolf HJ,, et al. Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003 ; 31: 815-832.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 815-832
-
-
Bjornsson, T.D.1
Callaghan, J.T.2
Einolf, H.J.3
-
21
-
-
40049084668
-
Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: Proposed refinement and expansion of the "rank order" approach
-
Rodrigues AD Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett. 2007 ; 1: 31-35.
-
(2007)
Drug Metab Lett
, vol.1
, pp. 31-35
-
-
Rodrigues, A.D.1
-
22
-
-
0033770918
-
Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation
-
Palovaara S., Kivistö KT, Tapanainen P., Manninen P., Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′- hydroxylation. Br J Clin Pharmacol. 2000 ; 50: 333-337.
-
(2000)
Br J Clin Pharmacol
, vol.50
, pp. 333-337
-
-
Palovaara, S.1
Kivistö, K.T.2
Tapanainen, P.3
Manninen, P.4
Neuvonen, P.J.5
Laine, K.6
-
23
-
-
0029987745
-
Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam
-
Zimmermann T., Yeates RA, Laufen H., Scharpf F., Leitold M., Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung. 1996 ; 46: 213-217.
-
(1996)
Arzneimittelforschung
, vol.46
, pp. 213-217
-
-
Zimmermann, T.1
Yeates, R.A.2
Laufen, H.3
Scharpf, F.4
Leitold, M.5
Wildfeuer, A.6
-
26
-
-
0021647847
-
The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam
-
Elliott P., Dundee JW, Elwood RJ, Collier PS The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. Eur J Anaesthesiol. 1984 ; 1: 245-251.
-
(1984)
Eur J Anaesthesiol
, vol.1
, pp. 245-251
-
-
Elliott, P.1
Dundee, J.W.2
Elwood, R.J.3
Collier, P.S.4
-
27
-
-
0142040171
-
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
-
Lam YW, Alfaro CL, Ereshefsky L., Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003 ; 43: 1274-1282.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 1274-1282
-
-
Lam, Y.W.1
Alfaro, C.L.2
Ereshefsky, L.3
Miller, M.4
-
28
-
-
0031028102
-
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
-
Ahonen J., Olkkola KT, Neuvonen PJ Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol. 1997 ; 51: 415-419.
-
(1997)
Eur J Clin Pharmacol
, vol.51
, pp. 415-419
-
-
Ahonen, J.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
29
-
-
0028359701
-
Dose of midazolam should be reduced during diltiazem and verapamil treatments
-
Backman JT, Olkkola KT, Aranko K., Himberg JJ, Neuvonen PJ Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol. 1994 ; 37: 221-225.
-
(1994)
Br J Clin Pharmacol
, vol.37
, pp. 221-225
-
-
Backman, J.T.1
Olkkola, K.T.2
Aranko, K.3
Himberg, J.J.4
Neuvonen, P.J.5
-
30
-
-
0027477751
-
A potentially hazardous interaction between erythromycin and midazolam
-
Olkkola KT, Aranko K., Luurila H., et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993 ; 53: 298-305.
-
(1993)
Clin Pharmacol Ther
, vol.53
, pp. 298-305
-
-
Olkkola, K.T.1
Aranko, K.2
Luurila, H.3
-
31
-
-
0031696409
-
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
-
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998 ; 64: 133-143.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 133-143
-
-
Gorski, J.C.1
Jones, D.R.2
Haehner-Daniels, B.D.3
Hamman, M.A.4
O'Mara, E.M.5
Hall, S.D.6
-
32
-
-
0029664974
-
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
-
Olkkola KT, Ahonen J., Neuvonen PJ The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996 ; 82: 511-516.
-
(1996)
Anesth Analg
, vol.82
, pp. 511-516
-
-
Olkkola, K.T.1
Ahonen, J.2
Neuvonen, P.J.3
-
33
-
-
33645847236
-
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
-
Saari TI, Laine K., Leino K., Valtonen M., Neuvonen PJ, Olkkola KT Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006 ; 79: 362-370.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 362-370
-
-
Saari, T.I.1
Laine, K.2
Leino, K.3
Valtonen, M.4
Neuvonen, P.J.5
Olkkola, K.T.6
-
34
-
-
7944237810
-
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
-
Kharasch ED, Walker A., Hoffer C., Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 ; 76: 452-466.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 452-466
-
-
Kharasch, E.D.1
Walker, A.2
Hoffer, C.3
Sheffels, P.4
-
35
-
-
36148968010
-
Drug interaction studies of therapeutic proteins or monoclonal antibodies
-
Mahmood I., Green MD Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol. 2007 ; 47: 1540-1554.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1540-1554
-
-
Mahmood, I.1
Green, M.D.2
-
36
-
-
41149106199
-
Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check
-
Seitz K., Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007 ; 47: 1104-1118.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1104-1118
-
-
Seitz, K.1
Zhou, H.2
-
37
-
-
0027530759
-
Human cholesterol synthesis measurement using deuterated water: Theoretical and procedure considerations
-
Jones PJ, Leitch CA, Li ZC, Connor WE Human cholesterol synthesis measurement using deuterated water: theoretical and procedure considerations. Arterioscler Thromb Vasc Biol. 1993 ; 13: 247-253.
-
(1993)
Arterioscler Thromb Vasc Biol
, vol.13
, pp. 247-253
-
-
Jones, P.J.1
Leitch, C.A.2
Li, Z.C.3
Connor, W.E.4
-
38
-
-
33645106219
-
Cholesterol-metabolizing cytochromes P450
-
Pikuleva IA Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 ; 34: 513-520.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 513-520
-
-
Pikuleva, I.A.1
-
39
-
-
45549087867
-
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin
-
Magnusson MO, Dahl ML, Cederberg J., Karlsson MO, Sandström R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008 ; 84: 52-62.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 52-62
-
-
Magnusson, M.O.1
Dahl, M.L.2
Cederberg, J.3
Karlsson, M.O.4
Sandström, R.5
-
40
-
-
47949115175
-
A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
-
Fahmi OA, Maurer TS, Kish M., Cardenas E., Boldt S., Nettleton D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008 ; 36: 1698-1708.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 1698-1708
-
-
Fahmi, O.A.1
Maurer, T.S.2
Kish, M.3
Cardenas, E.4
Boldt, S.5
Nettleton, D.6
-
41
-
-
54349113314
-
Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction
-
Shou M., et al. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos. 2008 ; 36: 2355-2370.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 2355-2370
-
-
Shou, M.1
-
42
-
-
27444445468
-
Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
-
Brown HS, Ito K., Galetin A., Houston JB Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2005 ; 60: 508-518.
-
(2005)
Br J Clin Pharmacol
, vol.60
, pp. 508-518
-
-
Brown, H.S.1
Ito, K.2
Galetin, A.3
Houston, J.B.4
-
43
-
-
71849114209
-
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivoeffects of itraconazole in man
-
Lütjohann D., Marinova M., Schneider B., Oldenburg J., von Bergmann K., Bieber T., Björkhem I., Diczfalusy U. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivoeffects of itraconazole in man. Int J Clin Pharmacol Ther. 2009 ; 47: 709-715.
-
(2009)
Int J Clin Pharmacol Ther
, vol.47
, pp. 709-715
-
-
Lütjohann, D.1
Marinova, M.2
Schneider, B.3
Oldenburg, J.4
Von Bergmann, K.5
Bieber, T.6
Björkhem, I.7
Diczfalusy, U.8
|